Objectives: To evaluate changes in pro-atherosclerotic biomarkers and endothelial function in patients initiating two different PI-based regimens as part of ART.
Introduction
HIV infection and combination ART are associated with increased cardiovascular risk and accelerated atherosclerosis. [1] [2] [3] Use of PIs has been associated with increased cardiovascular risk and this risk has been ascribed to the considerable impact of PI on lipid metabolism. 4, 5 In a previous cross-sectional study, Piconi et al. 6 found lower levels of pro-thrombotic and inflammation factors in HIV-infected individuals and higher metabolic factors (i.e. serum cholesterol and lipoproteins) in patients on ART compared with HIV-infected untreated individuals. They then hypothesized that HIV replication and inflammatory/thrombotic factors may be important proatherogenic factors in untreated HIV-infected individuals, whereas changes in metabolic parameters may be mainly involved in atherosclerosis in those using ART.
Moreover, a longitudinal analysis conducted on the Women's Interagency HIV Study (WIHS) cohort 7 showed an inverse correlation between the magnitude of increase in HDL cholesterol after ART initiation and the decrease in a number of pro-inflammatory markers, including soluble CD14, TNF-a, IL-2 soluble receptor (CD25) and MCP-1, among HIV-infected women.
Abnormal large artery function plays an important role in the pathogenesis of cardiovascular (CV) disease and increased arterial stiffness, which has been associated with all-cause and cardiovascular morbidity and mortality, can be investigated through the development of readily available non-invasive techniques that have been developed. 8, 9 Cross-sectional studies have shown elevated intima-media thickness (IMT), pulse-wave velocity (PWV) and reduced flow-mediated brachial artery dilation (FMD) in HIV-infected patients, especially during PI treatment. 10 However, in two different prospective studies ART was shown to have a beneficial effect on endothelial function, as measured by FMD in naive patients beginning treatment. 11, 12 Atazanavir/ritonavir and lopinavir/ritonavir are two PIs with slightly different impacts on lipids, glucose metabolism, kidney function and risk. 13 Moreover, in the A5257 randomized clinical trial 14 atazanavir/ritonavir showed a reduced increase in IMT as compared with the darunavir/ritonavir arm, possibly linked to the antioxidant effects of atazanavir/ritonavir-induced hyperbilirubinaemia.
The primary aim of this study was to evaluate the effects of two different PI regimens (atazanavir/ritonavir versus lopinavir/ritonavir) in a group of HIV-infected patients naive to ART at the beginning of the treatment and at 24, 48, 72 and 96 weeks after ART initiation on markers of immune reconstitution, immune activation and adhesion molecules. Moreover, we investigated changes in IMT, FMD and PWV after 24 weeks of ART.
Patients and methods

Ethics
This was a prospective, unblinded, randomized controlled trial (RCT) that lasted 24 weeks, followed by an observational follow-up study until week 96. The trial was registered at http://clinicaltrialregister.eu, EUDRACT number 2008-006644-19 and approved by the local ethics committee (Comitato Etico della Provincia di Monzana-Brianza). All patients gave written informed consent prior to enrolment in the study. The follow-up study (ancillary study), conceived 4 years after the end of the randomized one, started on 19 March 2015, after approval from the relevant ethics committee, the Comitato Etico della Provincia di Monza-Brianza.
Patients and study design
Eligible participants in the study were ART-naive HIV-1-infected adult patients attending the Division of Infectious Diseases, San Gerardo Hospital, MilanoBicocca University, Monza. All patients enrolled had the following inclusion criteria: documented HIV-1 infection, CD4 cell count .250 cells/mm 3 , no previous antiretroviral treatment, negative pregnancy test at least 14 days before the start of treatment, signed informed consent in accordance with Good Clinical Practice and local regulatory requirements prior to trial participation, and study drug susceptibility based on HIV-1 genotypic resistance test. Exclusion criteria were age ,18 years, pregnancy, a history of CV disease (myocardial infarction, angina pectoris, heart failure, stroke, transient ischaemic attacks and claudication), use of anti-aggregants, anti-coagulants or any other CV drugs except for antihypertensive agents, diabetes mellitus (defined as a fasting plasma glucose .126 mg/dL on two occasions, or use of antidiabetic drugs), uncontrolled hypertension [defined as systolic blood pressure (BP) 140 mmHg and diastolic BP 90 mmHg under treatment] and dyslipidaemia (defined as an LDL cholesterol 160 mg/dL, serum triglycerides 400 mg/dL or use of lipid-lowering drugs).
HIV-1-positive treatment-naive patients were prospectively enrolled in the RCT and randomized in a 1:1 allocation to Group A (atazanavir/ritonavir 300/100 mg q24h plus tenofovir/emtricitabine in a fixed-dose formulation q24h) or Group B (lopinavir/ritonavir 400/100 mg q12h plus tenofovir/emtricitabine in a fixed-dose formulation q24h) (Figure 1 ).
The ancillary study had the aim of retrieving the clinical and laboratory data of the enrolled patients from week 25 (i.e. after the end of the randomized study, up to week 96 after the start of randomized study) in order to examine the situation 18 months from the end of randomized treatment. Among the 27 patients included in the study, during this followup period, one patient in group A and five patients in group B changed ART regimens (see Figure 1) .
We assessed participants at screening, baseline and follow-up visits at weeks 4, 12 and 24. In addition, in the follow-up study, three visits were scheduled at weeks 48, 72 and 96 for all the previously randomized patients.
Considering the two studies at baseline and at weeks 4, 12, 24, 48, 72 and 96, patients were evaluated for: HIV RNA load; CD4! or CD8! cell absolute counts and percentages; triglycerides (TGs); total cholesterol (TC), LDL and HDL cholesterol; and glucose.
Height and body weight were recorded for all subjects, which allowed calculation of BMI. Glomerular filtration rate was estimated (eGFR) by the Modification of Diet in Renal Disease (MDRD) equation.
Functional and structural markers of atherosclerosis
At baseline and at 24 weeks, patients were subjected to evaluation of arterial functional properties (FMD and PWV) and a structural marker (carotid IMT). Measurements were made in the supine position in a quiet room in which the temperature was maintained at 22 C by two operators blinded to the subject's clinical status.
Aortic (carotid-to-femoral) PWV was obtained with an automatic applanation tonometry-based device, i.e. the SphygmoCor Vx system (AtCor Medical, Australia) as previously described by our group. 15 Common carotid artery IMT was measured with the subject supine and the neck in partial extension on the right side with a radio-frequency system as previously described. 15, 16 The value was corrected by a factor of 0.8 according to the PWV measurement methods consensus document, 8 which states that the subtraction method should be used instead of the direct one when assessing the distance between the two measurement points. The endothelium-dependent response was assessed as dilation of the brachial artery to increased flow (FMD), as described by Ghiadoni et al.
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Blood sample collection
Blood was collected by venepuncture in EDTA-containing Vacutainer tubes and analysed fresh (Becton Dickinson, Rutherford, NJ, USA). Plasma was stored at #80 C.
Immunophenotypic analysis
Cell subsets were evaluated using 50 lL of EDTA-treated peripheral blood incubated for 10 min at room temperature with fluorochrome-labelled monoclonal antibodies (MAbs): anti-CD4 PCy7 or PCy5, anti-CD8 PCy5 or FITC, anti-CD11a PE, anti-HLA-DRII PE, anti-CD25 PCy5 (Beckman Coulter, Fullerton CA, USA) and anti-CD44 PE (Serotec, Space Import Export Srl, Milan, Italy). Erythrocytes were then lysed and cells were fixed using the Immuno-Prep EPICS Kit and Q-prep Work Station (Coulter Electronics, Miami Lakes, FL, USA). Cytometry was performed on 200000 events using an EPIC XL flow cytometer (Beckman-Coulter). Data were analysed by first gating on the lymphocyte population as defined by forward and side-light scatters. From this population, a single-colour CD4! or CD8! histogram was made, and T cells were selected and inserted into a 2D dot plot.
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Plasma cytokine and chemokine concentrations
Plasma cytokine and chemokine concentrations (TNF-a, TNF-b, MCP-1 and MIP-1b) were analysed using a Multiplex ELISA Assay (Bioclarma Srl, Torino, Italia) and expressed in pg/mL.
Statistical analysis
An ITT analysis was performed (i.e. all randomized subjects, regardless of their compliance with the protocol, were included in the analysis) unless no trial medication had been taken at all. The median and IQR for each variable of interest are presented for the two treatment groups, for baseline, week 24 (i.e. last visit of the randomized study) and week 96 (i.e. the follow-up visit). Patients' characteristics at enrolment were tested for differences between treatment groups by the v 2 , Fisher's exact, Mann-Whitney or t test depending on variable type. The primary efficacy parameter was the difference between treatment groups in adhesion molecules and adhesion and activation markers during the treatment period (baseline/week 4/week 12/ week 24). The analysis of variance was used to evaluate differences between the two groups (the between-patient factor) over time (the within-patient factor), applying a mixed-model repeated measures analysis, with rank-transformed variables when the distributions were not normal. Secondary efficacy parameters were comparisons between the two treatment groups for measurements of FMD, IMT and PWV (baseline versus week 24). The Wilcoxon signed-rank test was used to evaluate differences between the two treatment groups over time (considering within-patient differences).
All the factors considered in the randomized study (i.e. laboratory data, adhesion molecules and activation markers) were evaluated at week 96 in the observational follow-up study and compared with week 24 values (i.e. the last visit of the randomized study). Analysis of variance was used to evaluate differences between the two groups (the between-patient factor) over time (the within-patient factor), applying a mixed-model repeated measures analysis, with rank-transformed variables when the distributions were not normal. Change of therapy during the follow-up period was considered a covariate.
An analysis of the entire population regarding adhesion molecule expression, not considering randomization, was also performed. Squillace et al.
Because of the exploratory nature of the study, there was no a priori evaluation of statistical power and sample size. Therefore, no correction for multiple comparisons was applied, and unadjusted P values are reported.
Statistical analyses were conducted using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA). A P value ,0.05 was considered to define a significant test.
Results
Patient characteristics
Twenty-seven patients were enrolled (Figure 1) ) and no differences in HBV and HCV infection prevalence were observed between the two groups. There were three patients with HCV infection (20%) in Group A and one (8.3%) in Group B. Given the small number of patients with HCV, a separate analysis was not performed.
No differences between treatments arms were registered at baseline, and BMI, systolic and diastolic BP, glucose and homeostatic model for insulin resistance (HOMA-IR) remained similar over time. Differences between treatment groups were registered for triglyceride levels, with a significant upward trend in Group B compared with Group A. As expected, significant differences between treatment groups were also registered for total bilirubin levels, with a significant upward trend in Group A compared with Group B (Table 1) .
After 18 months of follow-up (week 96) differences persisted for total bilirubin levels only, with median values comparable with those recorded at week 24.
Three patients in Group A and no patients in Group B were on antihypertensive therapy and no significant differences were found in systolic BP and diastolic BP between the two groups during follow-up period (Table 1 ).
Immunological and clinical parameters
As expected, during the overall treatment, CD4! T cell absolute count significantly increased and CD8! T cell count significantly decreased, with similar values registered in the two treatment arms. Consequently, the CD4!:CD8! ratio was found to be increased (Table 1) .
Changes in immune activation markers, adhesion molecules and soluble factors during the randomized study and the followup study are shown in Table 2 .
At week 24 changes in the expression of adhesion and immune activation molecules were observed in both CD4! T and CD8! T cells (helper and cytotoxic T cells, respectively), when compared with the baseline. In particular, the percentage of CD4! T cells expressing the adhesion molecules CD44 and CD11a (CD44!/CD4! and CD11a!/CD4! cells) was significantly increased for both treatments (Table 2 ). In contrast, a significant decrease was observed in the expression of CD44 and CD11a on CD8! cells (Table 2) . When immune activation markers were analysed, the percentage of CD4! T cells expressing CD25 (CD25!/CD4!) was found to be significantly decreased for both treatments, but no changes in expression of HLA-DRII (DRII) on CD4! T cells were reported. In the CD8! subset, the expression of HLA-DRII significantly decreased in both groups but with significant differences in median values between treatments (Table 2) . With regard to cytokine/chemokine concentrations in the plasma, only TNF-b showed a significant trend difference between treatments, with a marked increase in Group B only (Table 2) , whereas both MCP-1/CCL-2 and MIP-1b/CCL-4 significantly increased in both groups (Table 2) .
Data were collected at week 96 and compared with baseline and week 24. In the CD4! T cell subset, both adhesion markers considered (CD44 and CD11a) were found to be significantly increased in both groups, with significant differences between the two treatments over time. CD44!/CD8! cells continued to decrease in both groups; there were significant differences in median values between the two treatments, with similar trends over time ( Table 2 ). No differences were observed in the expression of activation markers (CD25 and HLA-DRII) on CD4! T cells, whereas on CD8! T cells a significant increase was detected in HLA-DRII especially in group B (Table 2) . MCP-1/CCL-2 continued to rise significantly in both groups (Table 2) .
Differences between treatments were recorded for HLA-DRII!/CD8!, CD44!/CD4! and CD11a!/CD4!, for which values in group A at week 96 remained similar to those measured at week 24, and an increase was observed in group B. Such apparent discrepancies between week 24 and week 96 could give us a first insight into the short-term versus long-term impact of PI treatment. Considering the analysis of membrane expression of adhesion molecules (CD44 and CD11a) spanning the overall 96 weeks of study, the expression of adhesion molecules on CD8! cells was significantly reduced at week 96 (Figure 2a and  c) . Conversely, the expression of CD44! and CD11a! on CD4! cells significantly increased upon ART treatment (Figure 2a and  d) . All adhesion molecule modulations were independent of changes in absolute CD4! and CD8! lymphocyte count, since they are expressed as a percentage.
Functional and structural markers of atherosclerosis
No differences were observed between Groups A and B regarding IMT, FMD and PWV measurements at baseline and week 24. Analysing the entire study population, IMT did not show a significant difference between baseline and week 24 (median value 560 versus 516 lm). FMD increased, but not significantly, considering the entire population (6.3% at baseline versus 6.9% at week 24; P " 0.79).
PWV showed minimal changes between baseline and week 24 (8.75 at baseline versus 8.85 at week 24).
Discussion
By studying the expression of immune adhesion molecules as well as structural and functional vascular parameters, our prospective study provides a detailed picture of the immunological and vascular impact of two different PIs in the first 96 weeks of therapy. We chose two PIs, atazanavir/ritonavir and lopinavir/ritonavir, that had already demonstrated different behaviours as regards lipid metabolism and cardiovascular risk. 13 As seen in previous studies, we
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demonstrated that ART initiation led to a decrease in markers of immune activation and of adhesion molecules on CD8! T cells, but not of adhesion molecules on CD4! T cells. We also found that treatment with atazanavir/ritonavir was associated with a longterm (96 weeks) decrease in HLA-DRII-expressing CD8! T cells and a significantly lower increase in CD44-and CD11a-expressing CD4! T cells compared with lopinavir/ritonavir treatment. CV disease has emerged as a major cause of morbidity and mortality in the HIV population. [1] [2] [3] 18 In addition to traditional CV disease risk factors, inflammation appears to be a major component of this enhanced risk. 19 Several recent studies demonstrated only a partial reduction of inflammation, immune activation and no or mild improvement in arterial inflammation despite early and complete viral suppression in both naive 20, 21 and treatmentexperienced patients. 22, 23 In our study, to better identify the effects of HIV replication and of ART initiation on immune cells involved in atherogenesis, we analysed HIV-infected patients naive to antiretroviral treatment without CV disease and with low CV risk scores and we compared the effects of atazanavir/ritonavir and lopinavir/ritonavir in an RCT.
In the first 24 weeks of treatment we found a significant decrease in expression of immune activation markers (HLA-DRII and CD25!) and of adhesion markers (CD44 and CD11a) on CD8! T cells with both treatments, thus confirming the beneficial effect of ART initiation. However, expression of CD44 on CD4! T cells increased over time between baseline and 24 weeks of treatment in both arms. Moreover, among soluble factors, our data show in both groups a similar significant increase in MCP-1/CCL-2 and MIP1b/CCL-4, which are chemokines involved in recruitment of monocytes to atherosclerotic lesions and have been recently linked to coronary artery calcium development under ART. 24 TNF-b, an inflammatory marker potentially linked to the development of metabolic syndrome, 25 showed a significant increase with lopinavir/ritonavir treatment only. Interestingly, CD44 and CD11a adhesion molecule expression levels on CD4! T cells after ART initiation were significantly increased, confirming data by Piconi et al. 6 Notably, expression of CD11a and CD44 adhesion molecules on lymphocytes favours the infiltration of these cells into the plaques, leading to potentially disastrous plaque ruptures in response to an occasional inflammatory stress. [26] [27] [28] [29] The expansion of CD4! T cells expressing adhesion molecules after ART initiation has been reported by Wu et al., 30 who found a direct correlation between CD4! T cell recovery under ART and CD11a expression. We found an increase in expression of CD11a on the surface of CD4! T cells that was not associated with CD4 cell count, confirming an independent role of this adhesion molecule as a risk factor for development of atherosclerosis irrespective of immune status.
The long-term effects of atazanavir/ritonavir-and lopinavir/ ritonavir-based ART have been evaluated in our study, as we extended observation of cellular and soluble biomarkers to 18 months (96 weeks) after the end of the randomized study. At the end of the follow-up study, a progressive reduction in immune activation and expression of CD44 and CD11a on CD8! T cells was observed, whereas soluble biomarkers, specifically MCP-1 and One patient changed regimen (switched to NNRTI) and five patients changed regimen (two switched to another PI and three to NNRTI), respectively. c Follow-up period: significant differences over time. Change of treatment was considered a covariate. d Treatment period: significant differences in median values between treatment with similar trends over time. Immune parameters and antiretrovirals JAC MIP-1b, continued to increase, thus confirming that excess CV disease risk in HIV-infected patients on ART may be related to increased monocyte recruitment into atherosclerotic plaques.
Interestingly, expression of adhesion molecules on CD4! T cells was different between the two arms, as patients treated with atazanavir/ritonavir displayed levels of CD44!/CD4! T cells and CD11a!/CD4! T cells at week 96 that were similar to those registered at week 24, whereas significant increases were observed in lopinavir/ritonavir-treated subjects. These results, together with the known lower metabolic impact of atazanavir/ritonavir, may explain the lower risk of cardiovascular disease in patients on an atazanavir/ritonavir regimen as shown in a recent study evaluating IMT progression and comparing atazanavir/ritonavir-versus darunavir/ ritonavir-containing regimens.
14 A protective role of hyperbilirubinaemia was recently hypothesized to explain this difference as a consequence of a lower level of oxidative stress and less endothelial dysfunction; 31, 32 this hypothesis is supported by our data. Evaluation of vascular structure and function in the two arms of the study showed no substantial differences in IMT in the first 24 weeks of treatment, probably owing to the short period of observation and the slow development of structural abnormalities in the carotid intima-media during atherosclerosis progression, in agreement with other studies.
12-14 Furthermore, we did not find significant changes in PWV in the entire sample or in either treatment arm; this might also be explained by the short period of observation. Studies with an extended follow-up evaluating PWV found faster PWV progression in HIV-infected patients, with an association with low CD4 nadir; 33, 34 in our study no patient had a CD4 nadir ,200 cells/mm 3 and perhaps this better immunological status could have influenced the results.
We did not find a difference in FMD between the two groups and no significant amelioration was found considering the entire population between baseline and week 24. These data are in contrast with those of Torriani et al. 11 and Arildsen et al., 12 who found an improvement in FMD in all the patients after beginning ART. Our results might be explained by a high level of inflammation in our samples during ART treatment independent of HIV viral load.
Conclusions
Our study has some limitations, including the small sample size, the lack of data about functional and structural markers of atherosclerosis after week 24, and the inability of the study to demonstrate cause and effect owing to its observational nature. In addition, we did not assess the potential impact on atherosclerotic CV disease risk of other infections (such as cytomegalovirus coinfection) or of translocation of gut microbial products. Host genetics were also not examined in this study.
Despite these limitations, the strength of this study is the careful characterization in a randomized trial of the effect of ART introduction with two different PI-based treatments on the expression of adhesion molecules and soluble factors associated with 
